الفهرس 
Introduction and aim of the workOnly 14 pages are availabe for public view
 |  | from | 203 |  |  |
| | | from | 203 | | |
Abstract
Immunohistochemical studies reported that colorectal cancer (CRC) is joined of high expression of c-Myc. Our study exhibited that c-Myc alone or combined with other markers can be a promising biomarker for CRC diagnosis. This study included colon cancer patients (n=80), benign growth patients (n=35) and normal individuals (n=30). c-Myc was recognized using western blotting and quantified by ELISA then Receiver-operating characteristic curve (ROC) was used for measuring its diagnostic performance. In colon cancer patients, c-Myc was identified at 62 KDa and detection rates of c-Myc increased in colon cancer patients (75.0%) than patients with benign growth (48.6%). Also, the mean c-Myc onco-protein level (OD) in colon cancer patients (1.6 ± 0.02) was significantly (P < 0.0001) higher than benign (1.1 ± 0.03). Additionally, both detection rate and level of c-Myc were significantly (P < 0.05) increased with late stages, lymph node invasion, distant organ metastasis and high grades. Based on ROC analysis, c-Myc yielded a good diagnostic performance for colon cancer detection, where it had an area under the curve (AUC) 0.87 (sensitivity75.0%, specificity 93.3%) to distinguish between colon cancer patients and normal individuals. Multivariate analysis yielded colon-score that had a valuable diagnostic power in colon cancer early diagnosis as it had AUC 0.89 in distinguishing between patients with benign growth and those with early stages (sensitivity 78.1%, specificity 81.8%). In conclusion, c-Myc can be used as an effective biomarker for colon cancer diagnosis particularly for differentiates early tumor stages from benign disorders.